Method for reducing the occurrence of infection in young children

US9427445B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9427445-B2
Application numberUS-201214127897-A
CountryUS
Kind codeB2
Filing dateJun 22, 2012
Priority dateJun 22, 2011
Publication dateAug 30, 2016
Grant dateAug 30, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The invention pertains to the use of a composition in reducing the number of infections episodes and the occurrence of infections in young children, said composition comprising: (a) long chain polyunsaturated fatty acids, wherein the amount of arachidonic acid is less than 0.06 gram per 100 gram fatty acid; and comprising, per 100 g fatty acids: (i) 0.3-0.6 gram docosahexaenoic acid; (ii) 0.2-0.4 gram eicosapentaenoic acid; and (b) between 1.5 and 2.5 gram indigestible oligosaccharides per 100 kcal, comprising: (i) 1.4-2 gram short-chain galactooligosaccharides; and (ii) 0.1-0.5 gram long-chain fructopolysaccharides.

First claim

Opening claim text (preview).

The invention claimed is: 1. A method for reducing occurrence of respiratory tract or intestinal infection in young children, reducing number of infectious episodes in respiratory tract or intestine in young children, and/or treatment of respiratory tract or intestinal infections in young children, the method comprising administering to young children suffering from respiratory tract infections a composition comprising: (a) long chain polyunsaturated fatty acids (LC-PUFAs) with 20 and 22 carbon atoms, comprising less than 0.06 gram arachidonic acid (ARA) per 100 gram total fatty acid; and (i) 0.3-0.6 gram docosahexaenoic acid (DHA, n-3) per 100 g total fatty acids; and (ii) 0.2-0.4 gram eicosapentaenoic acid (EPA, n-3) per 100 g total fatty acids; wherein the weight ratio of ARA:DHA is below 0.1 and the weight ratio of ARA:EPA is below 0.2; and one of (b1) or (b2): (b1) between 1.5 and 2.5 gram per 100 kcal indigestible oligosaccharides, comprising: (i) 1.4-2 gram galactooligosaccharides with a degree of polymerization of 2-7; and (ii) 0.1-0.5 gram fructopolysaccharides with a degree of polymerization of 2-150; or (b2) a daily amount of between 4 and 8 gram indigestible oligosaccharides, comprising, per day: (i) 3.7-6.4 gram galactooligosaccharides with a degree of polymerization of 2-7; and (ii) 0.3-1.6 gram fructopolysaccharides with a degree of polymerization of 2-150. 2. The method according to claim 1 , wherein at least 80 wt % of the LC-PUFAs is provided by a combination of EPA and DHA. 3. The method according to claim 1 , wherein the composition comprising 0.01-0.2 gram docosapentaenoic acid (DPA, n-3) per 100 g total fatty acids. 4. The method according to claim 1 , wherein the composition comprising 0.25-0.35 g EPA and 0.35-0.55 g DHA per 100 g total fatty acids. 5. The method according to claim 1 , wherein at least 95 wt % of the indigestible oligosaccharides is provided by the galactooligosaccharides and fructopolysaccharides. 6. The method according to claim 1 , wherein the composition comprising 8-10 en % protein, 45-55 en % carbohydrates and 35-45 en % fat; and has a caloric value of 0.5-0.75 kcal per 100 ml. 7. The method according to claim 1 , wherein the composition has an omega-6 LC-PUFA:omega-3 LC-PUFA weight ratio other than ARA:DHA and ARA:EPA between 1:1 and 7:1. 8. The method according to claim 1 , wherein the composition has a weight ratio of DHA:EPA in a range of 1:1 to 2:1. 9. The method according to claim 1 , wherein the composition further comprises vitamin D. 10. The method according to claim 9 , wherein the composition comprises vitamin D in a daily dosage of 200-800 μg.

Assignees

Inventors

Classifications

  • Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title

  • Drugs for disorders of the respiratory system · CPC title

  • Ageing or ripening by storing, e.g. lagering of beer · CPC title

  • Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula · CPC title

  • Comminuted fibrous parts of plants, e.g. bagasse or pulp · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9427445B2 cover?
The invention pertains to the use of a composition in reducing the number of infections episodes and the occurrence of infections in young children, said composition comprising: (a) long chain polyunsaturated fatty acids, wherein the amount of arachidonic acid is less than 0.06 gram per 100 gram fatty acid; and comprising, per 100 g fatty acids: (i) 0.3-0.6 gram docosahexaenoic acid; (ii) 0.2-0…
Who is the assignee on this patent?
Sijben Johannes Wilhelmus Christina, Alles Martine Sandra, Nutricia Nv
What technology area does this patent fall under?
Primary CPC classification A61K31/593. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Aug 30 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).